LexaGene successfully configures its MiQLab system to detect mutant sequences unique to UK and South African coronavirus variants
LexaGene Holdings Inc (CVE:LXG) (OTCQB:LXXGF) (FRA:5XS2) announced Wednesday it has successfully configured a MiQLab system to detect mutant sequences unique to the UK (B.1.1.7) and South African (B.1.351) variants of SARS-CoV-2, the coronavirus pathogen that causes the COVID-19 disease.
The UK variant, known to be more contagious and possibly deadlier, was first detected in the US at the end of December and has now been identified in 33 states. Likewise, both the South African and Brazilian variants were first detected in the US at the end of January, and several cases have now been reported in the US – suggesting more widespread infections.
LexaGene said the UK, SA, and Brazilian variants have now acquired mutations that may likely reduce the efficacy of approved vaccines and therapeutics.
READ: LexaGene Holdings initiates program to identify the UK and South African variants of coronavirus
The company’s MiQLab is designed for point-of-care use and for simultaneous screening of numerous respiratory pathogens, including COVID-19 strain identification. The system is open-access, which allows for new tests to be easily loaded onto the system. This is a unique feature that is not found in any other system designed for point-of-care use.
“Just three weeks ago, we designed assays to detect the UK and SA variants to demonstrate proof-of-principle that these assays could be quickly ported onto the MiQLab,” said Dr Jack Regan, LexaGene’s CEO and founder, in a statement.
“After just two full work days of having these reagents in-house, we verified our MiQLab could detect mutations associated with these variants. With proper FDA approvals, these tests could quickly be sent to MiQLabs operating at the point-of-care for faster detection, which would likely improve containment efforts for the spread of these new variants.”
Dr Regan added: “The optimism over the increasing availability of COVID-19 vaccines needs to be tempered with the worrisome potential that some of these new variants are not only more contagious, but also may render these vaccines less effective. Generally, getting a new vaccine authorized for use by FDA takes six or more months, so we really need to rely on better diagnostics to stop the spread of these new variants before they become more widespread and nearly impossible to contain. MiQLab’s open-access design allows the system to be quickly configured to detect new variants at the point-of-care. As such, our technology fills a critical testing gap we have in our defenses against these ever-changing pathogens.”
LexaGene is pursuing an Emergency Use Authorization (EUA) from the US Food and Drug Administration for COVID-19 testing using assays that are predicted to detect 99.9% of the strains circulating today based on published sequences – including the UK, South Africa, and Brazilian variants.
At this time, LexaGene said it has no plans to incorporate the variant-specific tests into the initial FDA studies for EUA for COVID-19 testing.
As is standard practice, until the FDA grants LexaGene’s instrument EUA for COVID-19 testing, all work using LexaGene instruments is classified as Research Use Only and cannot be used for human clinical diagnostics.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham
Story by ProactiveInvestors
Source: http://www.proactiveinvestors.com/companies/news/940949/lexagene-successfully-configures-its-miqlab-system-to-detect-mutant-sequences-unique-to-uk-and-south-african-coronavirus-variants-940949.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.
